

Macular Degeneration Guideline Committee – development

Date: Monday 13th February 2017

Location: NICE offices, London

Minutes: Final

Committee members present:	
Waqar Shah (Chair)	Present for all items
Katy Barnard (KB)	Present for all items
Nick Beare (NB)	Present for all items
Cathie Burke (CB)	Present for all items
Jennifer Evans (JE)	Present for all items
Alexander Foss (AF)	Present for all items
Mary Freeman (MF)	Present for all items
Carol McCletchie (CM)	Present for all items
Ellen Rule (ER)	Present until 3
Mary-Ann Sherratt (MS)	Present for all items
Elizabeth Wick (EW)	Present for all items
Cathy Yelf (CY)	Present for all items

In attendance:	
Louisa Crossley (LC) NICE – Senior Medicines Advisor	Present for all items
Sue Ellerby (SE) ICG – Clinical Advisor	Present for all items
Andrew Gyton (AG) Commissioning Manager	Present for all items
Gareth Haman (GH) Editor	Present from during item 4
Jayne Lynn	Present for all items

Macular Degeneration Guideline Committee 13 minutes

NICE – Business Analyst	
Vonda Murray (VM) ICG – Project Manager	Present for all items
Dave Nicholls (DN) NICE – Information Specialist	Present for all items
Joshua Pink (JP) ICG – Technical Advisor	Present for all items
Gabriel Rogers (GR) ICG – Technical Advisor (HE)	Present for all items

Apologies:	
Andy Charley	Committee member
Sue Ellerby	NICE – ICG, Clinical Advisor
Jamie Elvidge	NICE – ICG – Technical Analyst (HE)
Yingying Wang	NICE – ICG, Technical Analyst
Sue Spiers	NICE – ICG, Associate Director

Item 1 Introductions, apologies, minutes, DOI and objectives for the meeting		
<p>The Chair welcomed the Committee members and attendees to the 13th meeting on age-related macular degeneration (AMD). The committee members, and attendees and introduced themselves.</p> <p>Apologies were noted, as recorded above.</p> <p>The Chair invited each attendee to declare any new conflicts since the previous meeting. The following conflicts were noted;</p>		
Attendee	Declaration	Action
Waqaar	Presented at a conference 100%	Declare and participate

Shah	OPTICAL, at a session organised by the Worshipful Company of Spectacle Makers. The topic was community optometry, and did not include AMD. No payment received.	
------	---	--

Having reviewed all previous and new declarations of interest it was agreed that all committee members were eligible to attend the committee meeting and contribute to the discussions and drafting of any recommendations.

The minutes were reviewed from GComm 12; 5th January 2017. The minutes were agreed to be an accurate record.

The Chair provided an overview of the objectives for the day highlighting the information that would be discussed.

Item 2

RQ10) What is the effectiveness of treatment of neovascular AMD in people presenting with visual acuity better than 6/12?

RQ11) What are the indicators for treatment failing and switching?

RQ12) What is the effectiveness of different anti-angiogenic therapies (including photodynamic therapy) for the treatment of neovascular AMD?

RQ13) What is the effectiveness of adjunctive therapies for the treatment of neovascular AMD?

RQ14) What factors indicate that treatment for neovascular AMD should be stopped?

RQ15) What is the effectiveness of switching therapies for

neovascular AMD if the first-line therapy is contraindicated or has failed?

RQ18) What is the effectiveness of different frequencies of administration for anti-VEGF regimens for the treatment of neovascular AMD?

RQ25) What is the effectiveness of treatment of neovascular AMD in people presenting with visual acuity worse than 6/96?

GR presented the updated Health Economic model to the committee. JP presented the new evidence found in the reruns of the searches. The committee reviewed and revised the recommendations as appropriate.

LUNCH

Item 3

RQ10, RQ11, RQ12, RQ13, RQ14, RQ15, RQ18, RQ25 – continued

JP continued to present the new evidence. The committee reviewed and revised the recommendations as appropriate.

Item 4

Update search:

- **Diagnosis**
- **Referral**

JP presented new evidence around organisational models of care and referral pathway. The committee reviewed and revised the recommendations as appropriate.

JP presented new evidence for what tools are useful for triage, diagnosis, informing treatment and determining management in people with suspected AMD. The committee reviewed and revised the recommendations as appropriate.

JP led the committee in a review of the recommendations made for what signs and symptoms should prompt a healthcare professional to suspect AMD in people presenting to healthcare services, and revised the recommendations as appropriate.

Item 5

Review :

- **Classification**

- **Risk factors**
- **Information**
- **Non-pharmacological**
- **Frequency of monitoring**
- **Monitoring**

JP led the committee in a review of the recommendations that have been made to date on classification, risk factors, information, non-pharmacological, frequency of monitoring, and monitoring. The committee reviewed and revised the recommendations as appropriate.

Item 6
Consultation process

VM provided an overview of the next steps and key dates in preparing for the consultation process.

Item 7
Any other business

None

Item 7
Summary and next steps

The Chair thanked the committee for their time and contribution to the meeting. The venue, date and time of the next meeting were confirmed.

Date of next meeting: Post Consultation Meeting - Thursday 15th June 2017

Location of next meeting: NICE offices, Manchester